Brief: Lavipharm H1 Adjusted EBITDA At EUR 7.7 Million, Up 29.4% YoY
18/09/2025 15:59
Sept 18 (Reuters) - Lavipharm SA LPHr.AT: H1 NET PROFIT EUR 2.6 MILLION VERSUS EUR 7.7 MILLION YEAR AGO H1 ADJUSTED EBITDA EUR 7.7 MILLION VERSUS EUR 5.9 MILLION YEAR AGO H1 SALES AFTER DEDUCTION OF REBATES AND CLAWBACK EUR 26.7 MILLION VERSUS EUR 25.0 MILLION YEAR AGO LAVIPHARM SAYS PRIOR YEAR'S PROFIT BENEFITED FROM EUR 5.7 MILLION DEFERRED TAX ASSET RECOGNITION LAVIPHARM SAYS EXCLUDING THIS EXTRAORDINARY INCOME NET PROFIT IN H1 2025 WOULD BE UP 32% YOY Further company coverage: [LPHr.AT] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))
Recent news on Lavipharm SA
See all newsBrief: Lavipharm Q1 Earnings Before Tax From Continuing Operations €1.41 Million, Up 28.6% YoY
Brief: Lavipharm To Acquire Durogesic Pain Patch Rights From Janssen For $12.0 Million
Brief: Lavipharm SA FY 2025 Earnings After Tax EUR 6.0 Million Versus EUR 9.0 Million Year Ago
Brief: Lavipharm 9-Month Net Profit Down To EUR 3.5 Million
Brief: Lavipharm H1 Adjusted EBITDA At EUR 7.7 Million, Up 29.4% YoY